Document:

KINIKSA. Pano Separation Agreement (MBWL 1-28-2022) (00036499).DOCX

Exhibit 10.37
​

​
[***] Certain information in this document has been excluded pursuant to 
Regulation S-K, Item 601(a)(6). 
​

​
​
January 31, 2022
​
By Email
​
Arian Pano
[***]
​
Dear Arian:
​
The purpose of this letter agreement (“Agreement”) is to confirm the terms of your separation from Kiniksa Pharmaceuticals Corp. (“Kiniksa” or the “Company”).1 Unless you rescind your assent as set forth in Section 6(iii) below, this Agreement shall be effective on the eighth (8th) day after you sign it (the “Effective Date”), at which time it shall become final and binding on all parties. 
​
1.Separation Date. Your employment with the Company shall separate effective January 31, 2022 (the “Separation Date”). You acknowledge that from and after the Separation Date, you shall have no authority to represent yourself as an employee or agent of the Company, and you agree not to represent yourself in the future as an employee or agent of the Company. On or before the Separation Date, the Company shall pay your accrued but unused vacation time and your final pay earned through the Separation Date in accordance with applicable law. Regardless of whether you execute this Agreement, and provided you timely complete the required election forms (which will be provided to you separately), you are eligible to continue receiving group medical and/or dental insurance pursuant to Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) at your cost.
​
2.Consideration. If you do not rescind this Agreement as set forth in Section 6(iii) below, then the Company will provide you with the following (the “Consideration”) in accordance your Employment Agreement with the Company dated April 1, 2021 (the “Employment Agreement”): 
​
		(i)	a lump sum severance payment in the amount of $333,540.09, which is equivalent to nine (9) months of your annual base salary, less all applicable income and payroll taxes, deductions and withholdings, and less any amounts you may owe to the Company (the “Severance Payment”), which shall be paid within sixty (60) days after the Separation Date;

​

1.  Except for the obligations set forth in Section 2, which shall be solely the obligations of Kiniksa Pharmaceuticals Corp., whenever the terms “Kiniksa Pharmaceuticals Corp.,” “Kiniksa” or the “Company” are used in this Agreement (including, without limitation, Section 6), they shall be deemed to include Kiniksa Pharmaceuticals Corp. and any and all of its divisions, affiliates and subsidiaries and all related entities (including, without limitation, Kiniksa Pharmaceuticals, Ltd.) and its and their directors, officers, employees, agents, successors and assigns. 
​

​

​

		(ii)	a one-time, lump-sum bonus payment of $16,500.00, less all applicable income and payroll taxes, deductions and withholdings (the “One-Time Bonus”), which shall be paid within sixty (60) days after the Separation Date; 

​

		(iii)	a one-time, lump sum post-termination bonus of $12,971, which is equivalent to the pro-rata share of your 2022 Target Bonus, less all applicable income and payroll taxes, deductions and withholdings (the “Post-Termination Bonus”), which will be paid at or around the time that annual bonuses are paid to other similarly situated employees of the Company, but in no event later than March 15, 2023; and	

​
		(iv)
	twelve (12) months of accelerated vesting on any time-based unvested equity award(s) as of the Separation Date; for the avoidance of doubt, vesting will not be accelerated on any performance-based or partially performance-based equity awards and the exercisability of any vested equity awards shall continue to be governed by the applicable equity award agreements and plan(s).

​
3.Acknowledgments. You acknowledge and agree that:
​
		(i)
	this Agreement and the Consideration are neither intended to nor shall constitute a severance plan and shall confer no benefit on anyone other than Kiniksa and you; 

​
		(ii)
	unless you execute this Agreement, the Consideration provided for herein is not otherwise due or owing to you under any employment agreement (oral or written); 

​
		(iii)
	except for (a) any unpaid regular wages (including accrued but unused vacation time) earned through (and including) the Separation Date, which shall be paid by the Company on the Separation Date and (b) any vested monies due to you pursuant to any retirement programs in which you participate, you have been paid and provided all wages, vacation pay, holiday pay, earned paid sick time, bonuses, commissions and any other form of compensation or benefit that may be due to you now or which would have become due in the future in connection with your employment with or separation of employment from Kiniksa; and

​
		(iv)
	in order to be reimbursed for all outstanding business expenses that you may have incurred on behalf of the Company, all expense reports and supporting documentation must be submitted in accordance with Company policies within five (5) days after the Separation Date.  

​
4.Unemployment Insurance. After the Separation Date, you may seek unemployment benefits. Decisions regarding eligibility for and amounts of unemployment benefits are made by the relevant state agency, not by Kiniksa. Kiniksa will not contest any application you may make for unemployment benefits; provided that, under no circumstances shall Kiniksa provide false or misleading information to any governmental agency or representative.
​
5.Return of Company Property; Confidentiality; Trade Secrets; Non-Disparagement. You hereby agree to:
 ​
		(i)	promptly return to Kiniksa all property and documents (whether in hard copy or electronic form) of Kiniksa in your custody and possession ; 

​
		(ii)	abide by the terms of your Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement with the Company dated November 11, 2019 (the “Non-Competition Agreement”), a copy of which is attached hereto as Exhibit A (and the terms of which are hereby incorporated into this Agreement by reference), including promptly executing and delivering to the Company the Termination Certificate attached as Exhibit A thereto. You understand that nothing in this Agreement prohibits you from reporting possible violations of federal law or `regulation to any governmental agency or entity, including but not limited to the Department of 

2

​

​

			Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. You understand that you do not need the prior authorization of the Company to make any such reports or disclosures and that you are not required to notify the Company that you have made such reports or disclosures;

​
		(iii)	abide by any applicable common law and/or statutory obligations relating to the protection and non-disclosure of Kiniksa’s trade secrets and/or confidential and proprietary documents and information, and you specifically agree that you will not disclose any confidential or proprietary information that you acquired as an employee of Kiniksa to any other person or entity, or use such information in any manner that is detrimental to the interests of Kiniksa; Further, notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”; 

​
		(iv)	keep confidential and not publicize or disclose the existence and terms of this Agreement, other than to (a) an immediate family member, legal counsel, accountant or financial advisor, provided that any such individual to whom disclosure is made shall be bound by these confidentiality obligations; or (b) a state or federal tax authority or government agency to which disclosure is mandated by applicable state or federal law; and

​
		(v)	not make any statements that are disparaging about or adverse to the business interests of Kiniksa or which are intended to harm the reputation of Kiniksa, including, but not limited to, any statements that disparage any product, service, finances, employees, officers, capability or any other aspect of the business of Kiniksa.

​
Your breach of this Section 5 will constitute a material breach of this Agreement and, in addition to any other legal or equitable remedy available to Kiniksa, will relieve Kiniksa of the obligation to provide any Consideration not already paid and will entitle Kiniksa to recover any Consideration already paid.
​

3

​

​

6.Release of Claims. 
​
		(i)
	You hereby acknowledge and agree that by signing this Agreement and accepting the Consideration, you are waiving your right to assert any form of legal claim against Kiniksa (as defined in footnote number 1 to this Agreement) of any kind whatsoever from the beginning of time through and including the date on which you sign this Agreement, except for claims related to the Company’s failure to perform its obligations under this Agreement. Your waiver and release is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as “Claims”) against Kiniksa seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other costs) against Kiniksa up through and including the date on which you sign this Agreement. You understand that there could be unknown or unanticipated Claims resulting from your employment with Kiniksa and the termination thereof and agree that such Claims are intended to be, and are, included in this waiver and release.

​
		(ii)
	Without limiting the foregoing general waiver and release, you specifically waive and release the Company from any Claims arising from or related to your employment relationship with the Company or the termination thereof, including without limitation: 

​
(a)Claims under any local, state or federal discrimination, harassment, fair employment practices or other employment related statute, regulation or executive order, including, without limitation, the Massachusetts Fair Employment Practices Act (also known as Chapter 151B), the Age Discrimination in Employment Act (“ADEA”) and Title VII of the Civil Rights Act of 1964, each as they may have been amended through the Effective Date; 
​
(b)Claims under any local, state or federal employment related statute, regulation or executive order relating to wages, hours, whistleblowing, leaves of absence or any other terms and conditions of employment, including, without limitation, the Family and Medical Leave Act of 1993, the Worker Adjustment and Retraining Notification (WARN) Act, the Massachusetts Payment of Wages Law (Massachusetts General Laws Chapter 149, §§ 148, 150), Massachusetts General Laws Chapter 149 in its entirety and Massachusetts General Laws Chapter 151 in its entirety (including, without limitation, the sections concerning payment of wages, minimum wage and overtime), each as they may have been amended through the Effective Date. You specifically acknowledge that you are waiving any Claims for unpaid wages under these and other statutes, regulations and executive orders; 
​
(c) Claims under any local, state or federal common law theory; and 
​
(d)any other Claim arising under other local, state or federal law.
​
		(iii)
	Because you are over 40 years of age, you are granted specific rights under the Older Workers Benefit Protection Act (“OWBPA”), which prohibits discrimination on the basis of age. The release set forth in this Section 6 is intended to release any rights you may have against Kiniksa alleging discrimination on the basis of age. You have twenty-one (21) days to consider and accept the provisions of this Agreement, and you agree that any changes to this Agreement, whether material or immaterial, will not restart the running of this period. In addition, you may rescind your assent to this Agreement if, within seven (7) days after the date you sign this Agreement, you deliver a written notice of rescission. To be effective, such notice of rescission must be postmarked, and sent by certified mail, return receipt requested, or delivered within the seven-day period to Kiniksa Pharmaceuticals Corp., 100 Hayden Avenue, Lexington, MA 02421, Attn: Chief Legal Officer.

​

4

​

​

		(iv)
	Consistent with federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging the validity of this release under federal or state discrimination laws or from filing a charge or complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or similar state agency, or from participating in any investigation or proceeding conducted by the EEOC or similar state agency. Further, nothing in this release or Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under federal or state discrimination laws, or the Company’s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under federal or state discrimination laws.

​
(v)    The general release in this Paragraph 6 shall not limit any right you may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission. 
​
		(vi)	The general release in this Paragraph 6 is not affected or limited by the recitation of the specific releases in this Paragraph 6.

​
7.Cooperation. For a period of two (2) weeks following the Separation Date, you agree to make yourself available to Kiniksa, upon reasonable notice (either by telephone or, if Kiniksa believes necessary, in person) to assist Kiniksa in any matter relating to the services performed by you during your employment with Kiniksa including, but not limited to, transitioning your duties to others. 
​
8.No Prior Actions. You represent that you have not filed or asserted any cause of action, claim, charge or other action or proceeding against Kiniksa, and to the best of your knowledge, no other person, organization or entity has done so on your behalf.
​
9.Miscellaneous. 
​
		(i)	Except for (a) any equity awards or grants from the Company, as may be amended herein; (b) the Non-Competition Agreement; and (c) the Indemnification Agreement between you and Kiniksa Pharmaceuticals, Ltd. dated June 10, 2021, all of which shall remain in full force and effect, this Agreement supersedes any and all prior oral and/or written agreements, and sets forth the entire agreement between Kiniksa and you in respect to your separation from Kiniksa including, without limitation, the Employment Agreement.

​
		(ii)	No variations or modifications of this Agreement shall be deemed valid unless reduced to writing and signed by Kiniksa and you. 

​
		(iii)	The provisions of this Agreement are severable, and if for any reason any part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full.

​
		(iv)	The validity, interpretation and performance of this Agreement, and any and all other matters relating to your employment and separation of employment from Kiniksa, shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without giving effect to conflict of law principles. Both parties agree that any action, demand, claim or counterclaim relating to (a) your employment and separation of your employment, and (b) the terms and provisions of this Agreement or to its breach, shall be commenced in the Commonwealth of Massachusetts in a court of competent jurisdiction. 

​
		(v)	Both parties further agree that any such dispute shall be tried by a judge alone, and both parties hereby waive and forever renounce the right to a trial before a civil jury in any such dispute.

5

​

​

​
​
It is Kiniksa’s desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been encouraged and given an opportunity to consult with legal counsel. By executing this Agreement, you are acknowledging that (a) you have been afforded sufficient time to understand the provisions and effects of this Agreement and to consult with legal counsel; (b) your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress; and (c) neither Kiniksa nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.
​

6

​

​

​
If the foregoing correctly sets forth our arrangement, please sign, date and return the enclosed copy of this Agreement to me within the time frame set forth above, but in any event not on or before the Separation Date. 
​
Very truly yours,
​
KINIKSA PHARMACEUTICALS CORP. 
​
​
 /s/ Melissa Manno​ ​
Melissa Manno
Senior Vice President, Chief Human Resources Officer
​
​
Accepted and Agreed To:
​
​
 /s/ Arian Pano​ ​
Arian Pano
​
​
Dated: February 2, 2022

7

​

​

EXHIBIT A
​
Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement with the Company
​
[copy follows this page]
​

​

​

KINIKSA PHARMACEUTICALS CORP.
​
EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON­ COMPETITION AND NON-SOLICITATION AGREEMENT
​
In consideration and as a condition of my employment by Kiniksa Pharmaceuticals Corp. (together with any of its successors or assigns collectively, the "Company"), a Delaware corporation and wholly-owned subsidiary of Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (together with any of its successors or assigns collectively the "Parent"), my receipt of the compensation paid to me by the Company in the context of that employment, my access to of the Organization's confidential and proprietary business information and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, I, the undersigned, agree as follows. For purposes of all sections of this Employee Proprietary Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement (this "Agreement"), the term "Organization" shall include the Parent, the Company and all other subsidiaries of the Parent.
​

1.Nondisclosure of Proprietary Information.
​

(a)During the term of my employment, I may receive and otherwise be exposed, directly or indirectly, to technical and non-technical confidential and proprietary information of the Organization, including without limitation, information relating to the Organization's business, strategies, designs, products, services and technologies and any derivatives, improvements and enhancements related to any of the foregoing, or to the Organization's suppliers, customers or business partners (collectively "Proprietary Information"), regardless of whether such information is specifically designated as confidential and regardless of whether such information is in graphic, written, electronic or oral form. The term "Proprietary Information" shall be given its broadest definition and shall include, without limitation, unpublished patent applications and other intellectual property filings, ideas, Inventions (as defined below), techniques, works of authorship, models, compounds, compositions, products, product candidates, projects, know-how, methods, processes, algorithms, software programs, software source documents, patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, codes, formulae, information and trade secrets as well as financial information (including sales costs, profits, pricing methods), research data, clinical data, bills of material, customer, prospect and supplier lists, investors, business information, contracts and contractual relationships (including with third parties), business forecasts, sales and merchandising data, and business and marketing plans and any derivatives, improvements and enhancements related to any of the above. Information the Organization has obtained from third parties as to which any of the Organization has an obligation of confidentiality also constitutes "Proprietary Information."
​

(b)I acknowledge the confidential and secret nature of the  Proprietary Information and agree that the Proprietary Information is the exclusive and extremely valuable property of the Organization. Accordingly, I agree to not (i) disclose any Proprietary Information to any person or entity other than employees, directors, advisors, agents and potential business partners of the Organization who have undertaken an obligation of confidentiality, and (ii) use any Proprietary Information for any purposes (other than in the performance of my duty as an employee of Company) without written prior approval by an officer of the Company, either during or after my  employment with Company. Upon termination of my employment, I agree to cease using and to return to the Company all whole and partial copies and derivatives of the Proprietary Information, whether in my possession or under my direct or indirect control, provided that I am entitled to retain my personal copies of (i) my compensation records, (ii) materials distributed to shareholders generally, and (iii) this Agreement.
​

(c)I shall promptly notify my supervisor or any officer of the Company if I learn of any possible unauthorized use or disclosure of Proprietary Information and shall cooperate fully with the Organization to enforce its rights in such information.
​

​

​

(d)I understand that my obligations with respect to Proprietary Information shall not apply to information that (i) is actually in the public domain at the time of disclosure or enters the public domain following disclosure through no fault of mine, (ii) was already in my possession at the time of disclosure and obtained without breach of any obligations of confidentiality, or (iii) is obtained by me from a third party not under confidentiality obligations and without a breach of any obligations of confidentiality. Disclosure of Proprietary Information shall not be prohibited, however, to the extent required to comply with applicable laws or regulations, or with a valid court or administrative order, provided that I promptly notify the Company in writing of the existence, terms and circumstances of such required disclosure and consult with the Company on the advisability of taking legally available steps to resist or narrow such disclosure.
​

(e)Notwithstanding anything herein to the contrary, I acknowledge and understand that (i) I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a Trade Secret that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a Trade Secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii) if I file a lawsuit for retaliation for reporting a suspected violation of law I may disclose the Trade Secret to my attorney and use the Trade Secret information in the court proceeding, provided I file any document containing the Trade Secret under seal and do not disclose the Trade Secret, except pursuant to court order. For the purposes of this Section l(e), the definition of "Trade Secret" shall have the meaning under the laws of Massachusetts and under the Defend Trade Secrets Act of 2016.
​

(f)I understand that, subject to the forgoing, this Agreement does not limit my ability to communicate with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, and Agency Inspector General or any other federal, state or local governmental agency or commission (each a "Government Agency"), including to report possible violations of federal law or regulation or making other disclosures that are protected under the whistleblower provisions of federal law or regulation, or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice, to any Government Agency.
​

2.Property of the Organization. I acknowledge and agree that all notes, notebooks, memoranda, reports, files, drawings, blueprints, manuals, materials, data, e-mails and other papers and records of every kind, or other tangible or intangible materials which shall come into my custody or possession in the course of my employment with the Company, relating to any Inventions (as defined below) or Proprietary Information, whether created by me or others, shall be and are the sole and exclusive property of the Company or Parent, as applicable, to be used only in the performance of my duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company or Parent, and I agree to assign and do hereby assign to the Company (or the Parent as set forth in Section 3) any rights or interests I may obtain in any of the foregoing. I agree to surrender this property to the Company immediately upon termination of my employment with the Company, or at any time upon request by the Company. I further agree that any property situated on any part of the Organization's data systems or on any part of the Organization's premises and owned by any part of the Organization, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Organization personnel at any time with or without notice.  I further agree that in the event of termination of my employment with the Company I will execute a Termination Certificate substantially in the form attached hereto as Exhibit A.
​

3.Inventions.
​

(a)Disclosure and Assignment of Inventions. For the purposes of this Agreement, an "Invention" shall mean any idea, invention or work of authorship, including, without limitation, any documentation, formula, compound, composition, therapeutic concept or candidate, design, device, code, method, software, technique, process, discovery, know-how, concept, improvement, enhancement, development, machine or contribution, in each 

​

​

case whether or not patentable, copyrightable or eligible for trademark registration. I agree to make full and prompt disclosure of all Inventions promptly in writing to an officer of the Company or to attorneys of the Organization in accordance with the Organization's policies and procedures, and I agree to assign and do hereby assign to the Parent, without requirement of further writing, without royalty or any other further consideration, my entire right, title and interest throughout the world in and to all Inventions created or reduced to writing by me in the course of my employment by the Company and all intellectual property rights therein, including, but not limited to, all related patents, patent applications, trade secrets, trademarks, trademark applications, copyrights and copyrights applications. I also hereby assign to the Parent any Inventions that exist as of the effective date of this Agreement that, at the time of conception or reduction to practice, relate to the current or then-planned business or operations of the Organization or to the actual or anticipated research or development of the Organization, except for those Inventions that (a) I have an obligation to assign to a third party, or (b) are listed on Exhibit B. I hereby waive, and agree to waive, any moral rights I may have in any copyrightable work I create or have created on behalf of the Organization. I also hereby agree, that for a period of one year after the end of my employment with the Company, I shall disclose to the Company any Inventions that I create, conceive, make, develop, reduce to practice or work on that are created through the use of, or derived from, Proprietary Information.
​

(b)Certain Exemptions. The obligations to assign Inventions set forth in Section 3(a) apply with respect to all Inventions (a) whether or not such Inventions are conceived, made, developed or worked on by me during my regular hours of employment with the Company; (b) whether or not the Invention was made at the suggestion of the Organization; (c) whether or not the Invention was reduced to drawings, written description, documentation, models or other tangible form; and (d) whether or not the Invention is related to the general line of business engaged in by the Organization, but do not apply, however, to Inventions that (x) I develop entirely on my own time, or after the date of this Agreement, without using the Organization's equipment, supplies, facilities or Proprietary Information; (y) do not relate to the Organization's current or planned business, or actual or demonstrably anticipated research or development of the Organization at the time of conception or reduction to practice of the Invention; and (z) do not result from and are not related to any work performed by me, or at my direction, for the Organization. I hereby acknowledge and agree that the Company has notified me that, if I reside in the state of California, assignments provided for in Section 3(a) do not apply to any Invention which qualifies fully for exemption from assignment under the provisions of Section 2870 of the California Labor Code ("Section 2870"), a copy of which is attached as Exhibit C. If applicable, at the time of disclosure of an Invention that I believe qualifies under Section 2870, I shall provide to the Company, in writing, evidence to substantiate the belief that such Invention qualifies under Section 2870. I further understand that, to the extent this Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, Section 3(a) shall be interpreted not to apply to any Invention which a court rules and/or the Company agrees falls within such classes.
​

(c)Records. I will make and maintain adequate and current written records of all Inventions covered by Section 3(a). These records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, notebooks and any other format. These records shall be and remain the property of the applicable Organization at all times and shall be made available to the Company at all times.
​

(d)Patents and Other Rights. I agree to assist the Organization in preparing, obtaining, maintaining and enforcing patents, invention assignments and copyright assignments, and other proprietary rights in connection with any Invention covered by Section 3(a), and will otherwise assist the Organization as reasonably required by any Organization to perfect in the Parent the rights, title and other interests in my work product granted to the Parent under this Agreement (both in the United States and foreign countries). I further agree that my obligations under this Section 3(d) shall continue beyond the termination of my employment with the Company, but if I am requested by any the Organization to render such assistance after the termination of such employment, I shall be entitled to a fair and reasonable rate of compensation for such assistance, and to reimbursement of any expenses incurred at the request of the Organization relating to such assistance. If the applicable Organization is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified above, I hereby irrevocably designate and appoint the Parent and its duly authorized officers and agents as my agent and attorney-in-

​

​

fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Section 3(d) with the same legal force and effect as if executed by me.

(e)Prior Contracts and Inventions; Information Belonging to Third Parties.
​
(i)I represent and warrant that, except as set forth on Exhibit 8 hereto, I am not required to assign Inventions under any other contracts that are between me and any other person or entity, and in existence as of the effective date of this Agreement.
​
(ii)I further represent that (A) I am not obligated under any consulting, employment or other agreement that would affect the Organization's rights or my duties under this Agreement, and I shall not enter into any such agreement or obligation during the period of my employment by the Company, (8) there is no action, investigation, or proceeding pending or threatened, or any basis therefor known to me involving my prior employment or any consultancy or the use of any information or techniques alleged to be proprietary to any former employer, and (C) the performance of my duties as an employee of the Company do not and will not breach, or constitute a default under any agreement to which I am bound, including any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to engagement by the Company or if applicable, any agreement to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.
​
(iii)I have listed on Exhibit B hereto any current agreements to which I am bound that require me to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.
​
(iv)I will not, in connection with my employment by the Company, use or disclose to the Organization any confidential, trade secret or other proprietary information of any previous employer or other person to which I am not lawfully entitled.
​
(v)As a matter of record, I attach as Exhibit B of this Agreement a brief description of all Inventions made or conceived by me prior to my employment with the Company that I own or Control (as defined below) and desire to be excluded from this Agreement ("Background Technology"). If full disclosure of any Background Technology would breach or constitute a default under any agreement to which I am bound, including any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to engagement by the Company, I understand that I am to describe such Background Technology in Exhibit B at the most specific level possible without violating any such prior agreement. Without limiting my obligations or representations under this Section 3(e), if I use any Background Technology in the course of my employment or incorporate any Background Technology in any product, service or other offering of the Organization, I hereby grant the Organization a non-exclusive, royalty-free, perpetual and irrevocable, worldwide right to use and sublicense the use of Background Technology for the purpose of developing, marketing, selling and, supporting Organization technology, products and services, either directly or through multiple tiers of distribution, but not for the purpose of marketing Background Technology separately from Organization products or services. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Background Technology into any product, service or technology of the Organization without the Company's prior written consent. As used herein, the term "Control" means, with respect to any Invention, the right to transfer or grant a license to such Invention without violating the terms of any agreement with a third party or applicable law.
​
​

​

​

IN WITNESS WHEREOF, I have executed this Employee Proprietary Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement under seal as of November 11, 2019.
​
​
​
Employee (sign): /s/ Arian Pano​ ​
​
Employee (print): Arian Pano​ ​
​
Address: [***]​ ​
​
​
Date employment first commenced: 11/11/19​ ​
​
​
AGREED AND ACKNOWLEDGED:
​
​
​
KINIKSA PHARMACEUTICALS CORP.
​
​
By: /s/ Thomas Beetham​ ​
​
Name: Thomas Beetham​ ​
​
Title: EVP and Chief Legal Officer​ ​
​
​

​

​

EXHIBIT A
​
TERMINATION CERTIFICATE
​
l, the undersigned, hereby certify that I do not have in my possession, nor have I failed to return, any documents or materials relating to the business of Kiniksa Pharmaceuticals Corp. or its affiliates (the “Company”), or copies thereof, including, without limitation, any item of Proprietary information listed in Section 3 of the Company's Employee Proprietary Information, Inventions Assignment, Non- Competition and Non-Solicitation Agreement (the "Agreement") to which I am a party, but not including copies of my own employment records.
​
I further certify that I have complied with all of the terms of the Agreement signed by me, including the reporting of any Inventions (as defined in the Agreement) covered by the Agreement. 
​
I further agree that in compliance with the Agreement, I will preserve as confidential any information relating to the Company or any of its business partners, clients, consultants or licensees that has been disclosed to me in confidence du ring the course of my employment by the Company unless authorized in writing to disclose such information by an executive officer of the Company. I understand that, provided I comply with all other provisions of the Agreement, nothing herein or in the Agreement limits my ability to communicate with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, and Agency Inspector General or any other federal, state or local governmental agency or commission (each a “Government Agency”), including to report possible violations of federal law or regulation or making other disclosures that are protected under the whistleblower provisions of federal law or regulation, or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice, to any Government Agency.
​
​
Date:​ ​​ ​
(Employee’s Signature)
​
​
Date:​ ​​ ​
(Printed or Typed Name of Employee)
​
​

​

​

EXHIBIT B
​
List here prior contracts to assign Inventions that are between any other person or entity and you, and in existence as of the effective date of this Agreement.
​
N/A​ ​
​
​ ​​
​
​ ​​
​
List here prior contracts that are now in existence that require you to refrain from competing directly or indirectly, wit the business of any previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.
​
Galapagos Employment Agreement​ ​
​
​ ​​
​
​ ​​
​
List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Please include any relevant patent and patent application numbers, if available. Continue on reverse side if necessary.
​
N/A​ ​
​
​ ​​
​
​ ​​
​
​

​

​

Exhibit C
​
CALIFORNIA LABOR CODE
​
California Labor Code § 2870. Application of provision providing that employee shall assign or offer
to assign rights in invention to employer
​
	(a) 
	Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities, or trade secret information except for those inventions that either:

​
		(1) 
	Relate at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development of the employer; or

​
(2) Result from any work performed by the employee for the employer.
​
	(b) 
	To the extent â provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

​Exhibit 10.38
​
​
​
​
EXCLUSIVE LICENSE AGREEMENT
​
by and between
​
​
​
The Beth Israel Deaconess Medical Center and
Primatope Therapeutics Inc.
​
​
​
dated as of November 1, 2013
​
[***] Certain information in this document has been excluded pursuant to 
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
-1-
​

LICENSE AGREEMENT
​
​
THIS AGREEMENT is made as of November 1, 2013 by and between The Beth Israel Deaconess Medical Center, Inc., a Massachusetts nonprofit corporation, having its principal place of business at 330 Brookline Avenue, Boston, MA 02215 ("Licensor"), and Primatope Therapeutics Inc, Inc. a for-profit corporation having a place of business at 508 Dudley Road, Suite 400 Newton, MA 02459 ("Licensee").
​
WHEREAS Licensor co-owns the Licensed Patent (as hereinafter defined) with Emory University ("Emory") and has a written agreement with Emory allowing Licensor to act on Emory's behalf in the execution of this Agreement; and
​
WHEREAS Licensor desires to have Licensed Technology, as hereinafter defined, developed and used for the benefit of the Licensor and the public in accordance with 35 U.S.C.
§ 200 et seq. and the regulations promulgated thereunder, as amended (hereinafter referred to as the "Federal Patent Policy"); and
​
WHEREAS Licensee wishes to obtain an exclusive license to make, have made, use, lease and sell products covered by the Licensed Patent in accordance with the Federal Patent Policy and the terms and conditions of this Agreement; and
​
WHEREAS Licensor wishes to grant such license to Licensee under the terms and conditions as set forth in this Agreement; and
​
Licensor and Licensee have therefore agreed as follows:
​
​

		1.	DEFINITIONS

​
The following terms shall have the meanings indicated in this Agreement.
​

		1.1	Agreement shall mean this Agreement, including all schedules and attachments

hereto.
​

1.2Affiliate shall mean any company, corporation, business or entity controlled by, controlling, or under common control with either Licensee or Licensor. For this purpose, "control" means direct or indirect beneficial ownership of at least fifty percent (50%) interest in the voting stock (or the equivalent) of such corporation or other business or having the right to direct, appoint or remove a majority or more of the members of its board of directors (or their equivalent), or having the power to control the general management of such company, corporation, business or entity, by contract, law or otherwise.
​
		1.3	Applicable Percentage -- see Schedule 3.1(iii) attached hereto.

​

​

1.4Biological Materials means tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described on Exhibit A, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as, recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). Exhibit A shall be periodically amended to include any additional Biological Materials that Medical School may furnish to Company
​
1.5Combination Product shall mean a product that includes the Licensed Product and one or more therapeutically useful products other than the Licensed Product.
​

1.5Confidential Information shall mean any and all information of or about a Party including all information relating to any technology, product, process or intellectual property of such Party (including, but not limited to, owned or licensed intellectual property rights, data, know-how, samples, technical and non-technical materials and specifications) as well as any business plan, financial information or other confidential commercial information of or about such Party. Notwithstanding the foregoing, information of or about a Party shall not be considered Confidential Information with respect to such Party to the extent that the Party possessing such information can demonstrate by written record or other suitable competent evidence that:
​
		(i)	such information was lawfully in such Party's possession or control prior to the time such information was disclosed to such Party by the Party to whom the information relates;	

​
		(ii)	such information was developed by such Party independently of and without reference to Confidential Information, provided, however that without limiting the generality of the foregoing, the Confidential Information of Licensor shall not become Confidential Information of Licensee by virtue of this Agreement;	

​

(iii)such information was lawfully obtained by such Party from a third party under no obligation of confidentiality to the Party to whom such information relates; or
​

		(iv)	such information was at the time it was disclosed or obtained by such Party, or thereafter became, publicly known otherwise than through a breach by such Party of such Party's obligations to the Party to whom such information relates.	

​
		1.6	Effective Date shall mean November 1, 2013.

​

​

1.7Federal Patent Policy shall mean 35 U.S.C. § 200 et seq. and all regulations promulgated thereunder, as amended, and any successor statutes or regulations.
​
		1.8	Licensed Field shall mean the field described in Schedule 1.8.

​
		1.9	FDA shall mean the United States Food and Drug Administration.

​
		1.10	Licensed Patents shall mean any of the patent applications described on Schedule 1.10 that may issue, together with any provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, renewals or extensions thereof or substitutes therefor, of the foregoing, and any foreign counterparts, and any patent issuing therefrom.	

​
1.11Licensed Know-how shall mean all technology, inventions, technical information, biological materials and the like, whether patentable or not, that are
​
		(i)	related to any patent applications or patents included in the Licensed Patents that were discovered, invented or developed by the inventors of the Licensed Patents prior to the Effective Date of this Agreement;	

​
		(ii)	which is necessary or useful in connection with the manufacture, use or sale of any product described in any such patent application or patent; and	

​
		(iii)	which constitutes and continues to constitute Confidential Information of the Licensor.	

​
		1.12	Licensed Territory shall mean any te1Titory described in Schedule 1.12.

​
		1.13	Licensed Technology shall mean the Licensed Patents, Biological Materials, and the Licensed Know-how.	

​
		1.14	Licensed Product shall mean

​

(i)any product the manufacture, use or sale of which would be covered by a Pending Claim, or absent the license granted by Licensor to Licensee herein, infringe any Valid Claim included in any Licensed Patent; or
​

		(ii)	any product the manufacture, use or sale of which could not be commercialized without the incorporation or use in whole or in part of some or all of the Licensed Know-how; or any product developed in whole or in part through use of a process which is of material importance to the development of the product and which is covered by a pending claim or Valid Claim included in any Licensed Patent.	

​

​

1.15Net Sale shall mean
​
		(i)	in any case where any Licensed Product is sold or commercially disposed of for value, whether or not in an arm's length transaction, to an independent third party, the gross amount received for such Licensed Product, less the following permitted deductions to the extent that such	

items are reflected in the price charged and do not exceed reasonable and customary amounts in the country in which the transaction occurs: (a) trade and/or quantity discounts, or rebates actually taken or allowed, (b) credits or allowances given or made for rejections or return of any previously sold Licensed Product actually taken or allowed, (c) any tax or government charge (including any tax such as a value added or similar tax or government charge, but not including any tax levied with respect to income) levied on the sale, transportation, export, import, deliver or use of the Licensed Product and born by the seller thereof, (d) any charges for freight or insurance billed to the final customer, and (e) sales commissions that are actually granted to a third party distributor or selling agent;
​
​

		(ii)	in any case where Net Sales are to be calculated for a Licensed Product included in a Combination Product, the total Net Sales of the Combination Product shall be multiplied by a fraction, A/A+B, where A is the gross selling price per unit, during the royalty-paying period in question, of the Licensed Product, and B is the gross selling price per unit of all other therapeutically useful components within the Combination Product sold during the royalty period in question. All calculations shall be performed on a country-by-country basis. As used herein, a "unit" shall mean the therapeutically useful content of the Licensed Product or Combination Product.	

​
1.16First Commercial Sale shall mean the first bona fide arm's length sale to the general public of Licensed Product in any country following receipt of all regulatory approvals necessary to commence regular commercial scale sales of Licensed Product in such country.
​
1.17Party shall mean each party to this Agreement and their respective successors and permitted assigns.
​

1.18Pending Claim shall mean a claim directed to subject matter of a patent application pending in a United States or foreign Patent Office.
​

1.19Sublicensee shall mean any third party to whom Licensee grants a sublicense of some or all of the rights granted to Licensee under this Agreement.
​

​

1.20Valid Claim shall mean a claim of an issued and unexpired patent included within the Licensed Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.
​
​
		2.	LICENSE

​
2.1Grant of License. Licensor hereby grants to Licensee an exclusive, royalty- bearing license, including the right to grant sublicenses, under the Licensed Patents, to make, have made, use, have used, import, have imported, offer for sale, sell, and have sold Licensed Products in the Licensed Territory in the Licensed Field. Licensor also grants to Licensee a non-exclusive royalty-bearing license to the Licensed Know-How. In addition to the other terms and conditions of this Agreement, the license granted hereby is subject to the following:
​
		(i)	Federal Patent Policy. To the extent that any invention included within the Licensed Technology has been partially funded by the United States Government, the United States Government retains certain rights in such research as set forth in the Federal Patent Policy. As a condition of the license granted hereby, Licensee shall comply with all commercially reasonable aspects of the Federal Patent Policy applicable to the Licensed Technology in the Licensed Territory in the Licensed Field. Nothing contained in this Agreement obligates or shall obligate Licensor to take any action which would conflict in any respect with its past, current or future obligations to the U.S. Government under the Federal Patent Policy with respect to the Licensed Technology in regard to work already performed or to be performed by Licensor. However, Licensor shall use its best efforts to take all necessary action to reserve for Licensee exclusive rights to the Licensed Technology in the Licensed Territory in the Licensed Field to the extent permitted under the Federal Patent Policy.	

​
		(ii)	Pre-existing Third Party Rights. All rights granted by Licensor to Licensee hereunder are subject to those pre-existing third party rights described on Schedule 2.l(ii).	

​

		(iii)	Licensor's Retained Rights. All rights granted by Licensor to Licensee hereunder are subject to the Licensor's retained rights which are as follows:	

​
Notwithstanding the exclusive rights granted to Licensee hereunder, Licensor retains, for itself and its Affiliates, a royalty­ free right to make and use Licensed Products or use Licensed
​

​

Technology solely for research (including clinical research), teaching or other scientific or academic purposes.
​
Additional retained rights, if any, are set forth at Schedule 2.1(iii).
​
2.2Sublicensing. Licensee shall have the right to grant sublicenses consistent with the terms and conditions of this Agreement provided that Licensee shall be responsible for the operations of any Sublicensee relevant to this Agreement as if such operations were carried out by Licensee itself, including (without limitation) the payment of any royalties or other payments provided for hereunder, regardless of whether the terms of any Sublicense provides for such amount to be paid by the Sublicensee directly to Licensor. Except as Licensor may in its discretion otherwise agree in writing, any sublicense granted by Licensee under this Agreement shall provide for termination upon termination of this Agreement.  The standard form of any sublicense agreement shall be consistent with the foregoing terms and other applicable provisions of this Agreement and shall be subject to prior approval by Licensor, which approval shall not be unreasonably withheld. Once Licensee obtains pre-approval of Licensor of the Standard Form Agreement, prior approval of sublicensing agreements by Licensor is not required; provided, however, Licensee shall obtain Licensor's prior written approval of the identity of each sublicensee, which approval shall not be unreasonably withheld. Licensee shall provide to Licensor a copy of all sublicense agreements within thirty days of executing the same.
​

		2.3	Restriction of other Rights. No license is granted to any right not specifically listed or referenced in this Agreement.	

​
​

		3.	CONSIDERATION, RECORD-KEEPING AND PAYMENTS

​
		3.1	Payments and Other Consideration.

​
(i)Licensing Fees. Licensee shall pay to Licensor those licensing fees specified in Schedule 3.1(i), at the time and in the manner specified therein.
​

(ii)Equity Interest. As partial consideration of the License Fee (i), Licensee shall issue to Licensor shares of [***] as specified in Schedule 3.1 (ii).
​
		(iii)	Running Royalties. Licensee shall pay or cause to be paid to Licensor a running earned royalty to the Applicable Percentage of all Net Sales of any Licensed Product by Licensee or any Sublicensee as specified in Schedule 3.1(iii), at the times and in the manner specified therein.	

​
(iv)Minimum Royalties. Licensee shall pay to Licensor the minimum royalty payments specified on Schedule 3.l(iv), at the times and in the manner specified therein.
​

​

		(v)	Milestone Payments. Licensee shall pay or cause to be paid to Licensor those milestone payments specified in Schedule 3.1(v), on the terms and conditions specified therein.	

​
		(vi)	Sublicensing and Other Fees. Licensee shall pay to Licensor those sublicensing fees specified in Schedule 3.1(vi).	

​
​
3.2Records. During the term of this Agreement and for [***] years thereafter, Licensee shall keep complete and accurate records of Licensee's and any Sublicensee's sales of Licensed Product and such other matters as may affect the determination of any amount payable to Licensor hereunder in sufficient detail to enable Licensor or Licensor's representatives independent authority to determine any amounts payable to Licensor under this Agreement. Licensee shall permit Licensor or its representatives, upon ten days prior notice and not more than once each calendar year, to examine its books, ledgers, and records, at a location where such records are maintained or other location mutually convenient for the parties, during regular business hours solely for the purpose of, and to the extent necessary, to verify any report required under this Agreement or the accuracy of any amount payable
hereunder. Licensee shall also permit Licensor or its representatives, upon ten days prior notice to Licensee, to examine not more than once each calendar year, any documents relating to its sublicensing of the Licensed Technology, at a location where such records are maintained or other location mutually convenient for the parties, during regular business hours. Should any examination conducted by Licensor or its representatives pursuant to the provisions of this paragraph result in an increase of more than [***]% in any payment due Licensor hereunder, Licensee shall be obligated to pay any reasonable out of pocket expenses incurred by Licensor with respect to such examination.
​
3.3Reports. Upon initiating commercial sales within 90 days after March 31, June 30, September 30 and December 31 of each year, Licensee shall deliver to Licensor a true and accurate report, giving such particulars of the business conducted by Licensee and any Sublicensees during the preceding three (3) calendar months under the Agreement, as are pertinent to an accounting for any royalty or other payments hereunder. If no payments are due, it shall be so reported.
​
3.4Form of Payment; Taxes. All amounts payable to Licensor hereunder shall be payable in United States funds without deductions for taxes, assessments, fees, or charges of any kind. Licensee shall be responsible for the payment of all withholding taxes imposed by any country on any royalty or other payment payable to Licensor hereunder and the percentage or other amounts payable to Licensor hereunder shall not be reduced to reflect the payment of any such withholding tax. All amounts payable to Licensor hereunder shall be payable in United States dollars in Boston, Massachusetts, or at such other place as Licensor may reasonably designate, provided, however, that if the law of any foreign country prevents any payment payable to Licensor hereunder to be made in Boston, Massachusetts, or as otherwise designated by Licensor or prevents any such payment to be made in United States dollars,
​

​

Licensor agrees to accept such royalty in form and place as permitted, including deposits by Licensee in the applicable foreign currency in a local bank or banks in such country designated by Licensee. If any currency conversion is required in connection with any payment to Licensor hereunder, such conversion shall be made at the buying rate for the transfer of such other currency as quoted by The Wall Street Journal on the last business day of the applicable accounting period, in the case of any payment payable with respect to a specified accounting period, or, in the case of any other payment, the last business day prior to the date of such payment.
​
3.5Interest.In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the first day following the calendar quarter to which such payment relates calculated at the annual rate of the sum of (a) [***] plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment is due, or on the date the payment is made, whichever is higher, the interest being compounded on the last day of each calendar quarter, provided that in no event shall said annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such royalty payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Licensor to any other remedy, legal or equitable, to which it may be entitled because of the delinquency of the payment.
​
​
		4.	PROTECTION OF INTELLECTUAL PROPERTY RIGHTS

​

4.1Patent Prosecution/Patent Costs. Licensor and Licensee shall prosecute and maintain the Licensed Patents as provided in Schedule 4.1.
​
4.2Confidential Information. Each Party shall maintain the Confidential Information of the other Party in confidence to the same extent that such Party maintains and protects its own Confidential Information, and shall not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement or with the express written consent of Party who provided such Confidential Information. Each Party also hereby agrees to take reasonable steps to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its directors, officers, employees, consultants, sub­ contractors, sub-licensees or agents. The provisions of this paragraph shall not apply to any Confidential Information of a Party which is required to be disclosed by another Party to comply with any applicable laws or regulations, but only to the extent required by such law or regulation and further provided that the Party making any disclosure pursuant to the provisions of this sentence shall provide prior written notice of such disclosure to the other Party sufficiently in advance of such disclosure to allow such other Party to respond and to take reasonable and lawful action to avoid and/or minimize the degree of such disclosure.
​

4.3Enforcement of Intellectual Property Rights. In the case of any infringement of any Licensed Patent or any violation of any other intellectual property right contained in the Licensed Technology by any third party (an "Infringer") in the Licensed Field in the Licensed
​

​

Territory during the term of this Agreement, Licensee shall have the right and the obligation, at Licensee's expense, to cause such third party to cease such infringement and to otherwise enforce such Licensed Patent or such other intellectual property right. Licensor shall assist Licensee as reasonably requested, at Licensee's expense, in taking any such action against any such Infringer.  Any amount recovered as a result of any action taken by Licensee hereunder shall [***]. If, following reasonable notice from the Licensor, Licensee shall fail to take any action against any Infringer which Licensor may reasonably deem necessary or desirable to prevent such infringement or violation, or to recover damages therefor, in addition to any other remedy available to it, Licensor may, upon notice to Licensee, take any steps Licensor may deem appropriate against such Infringer at Licensor's own expense. Licensee shall assist Licensor, at Licensor's expense, as reasonably requested in taking any such action against any such Infringer. Any amount recovered as a result of any such action taken by Licensor shall be [***]. This paragraph shall survive the termination or expiration of this Agreement.
​
4.4Infringement of Third Party Rights. Licensee shall promptly advise Licensor in writing of any notice or claim of any infringement and of the commencement against it of any suit or action for infringement of a third party patent made or brought against Licensee and based upon or arising under the license granted under this Agreement. In such event, Licensee shall have at all times the right to immediately cease commercialization and the right either to:
​

		(i)	request that Licensor enter into negotiations with such third party, wherein such negotiations shall be conducted in collaboration with Licensee, to obtain rights for Licensee under the third party patent;	

​
		(ii)	request that Licensor, in collaboration with Licensee, defend such claim, suit or action at the parties joint effort and expense; or	

​
		(iii)	terminate this Agreement.

​
Licensor shall not be obligated to enter into negotiations with such third party to obtain rights for Licensee under the third party patent nor obligated to defend such claim, suit or action. If Licensor, in its sole discretion, elects to enter into negotiations with such third party to obtain rights for Licensee under the third party patent or if Licensor, in its sole discretion, elects to undertake at its own expense the defense of any such claim, suit or action, Licensee shall render Licensor all reasonable assistance that may be required by Licensor in the negotiations or in the defense of such claim, suit or action. Licensor has the primary right to control the defense of any such claim, suit or action by counsel of its own choice, suit or action in respect of which Licensee is a defendant by counsel of its own choice. The Parties agree to cooperate reasonably in any such defense.
​

​

Notwithstanding the foregoing, if Licensor has not within [***] days (or such lesser period of time as is necessary to avoid entry of a default judgment against Licensor or Licensee) from the date of receipt of request from Licensee, either entered into negotiations with such third party to obtain rights for Licensee under the third party patent or initiated legal action to defend such claim, suit or action, it shall, upon written request of Licensee, grant to Licensee the right to enter into such negotiations or defend such claim, suit or action. Licensee shall be entitled to deduct all reasonable expenses (including legal fees) incurred in entering into such negotiations or defending such claim, suit or action from royalties due Licensor.
Licensee shall not settle or compromise any such suit or action without the written consent of Licensor, which consent shall not be unreasonably withheld or delayed.
​
​
​
		5.	OPERATION UNDER THE LICENSE

​
		5.1	Due Diligence.

​

		(i)	General Obligation. Licensee shall use commercially reasonable efforts, which efforts shall not be less than the efforts expended by Licensee in connection with its other high priority development projects, to diligently commercialize the Licensed Technology. In the event that Licensee shall fail to comply with its general due diligence obligations under this paragraph, Licensee shall (i) within [***] days of Licensee's receipt of written notice of such failure, provide to Licensor a commercially reasonable plan to remedy such failure within a time period not to exceed [***] days from the date of Licensee's receipt of such notice and (ii) cure such failure in accordance with such plan within the time provided for under such plan.	

​
(ii)Specific Due Diligence Obligations. Licensee shall also comply with each of the more specific due diligence requirements specified in Schedule 5.1.
​
		(iii)	Reports. Licensee shall provide to Licensor at least once per year a report on its activities and efforts toward commercialization of the Licensed Technology in sufficient detail to allow Licensor to monitor Licensee's compliance with the due diligence provisions of this Agreement and shall provide to Licensor those additional reports, if any, specified in Schedule 5.1.	

​
5.2Compliance with Law. Licensee shall comply with and shall insure that any Sublicensee complies with all government statutes and regulations that relate to Licensed Products, including, but not limited to, FDA statutes and regulations and the Export Administration Act of 1979 (50 App. U.S.C. §2401 et.seq.), as amended, and the regulations promulgated thereunder, and any applicable similar laws and regulations of any other country.
​

​

Without limiting the generality of the foregoing, Licensee agrees that all Licensed Products used or sold in the United States shall be manufactured substantially in the United States to the extent required by and in compliance with the Federal Patent Policy.
​
5.3Marking. In addition to any markings which Licensee may, in its sole discretion, place on the Licensed Products, Licensee shall cause all Licensed Products sold in the United States to be marked with all applicable U.S. Patent Numbers, to the full extent required by the United States law. Licensee shall similarly cause all Licensed Products and products shipped to or sold in any other country to be marked in such a manner as to conform with the patent laws and practice of such country.
​
5.4Publicity. Except as required by law, neither Licensor (and additionally Emory and Harvard) nor Licensee shall use the name of the other or its Affiliates, nor that of any staff member, employee, or student of the other or its Affiliates, or any adaptation thereof, in any advertising, promotional sales literature, offering materials, business plan or any other form of publicity without prior written consent obtained from the other party and from the individual staff member, employee or student if such individual's name is so used.
​
5.5Licensor Policies. Licensee acknowledges that Licensor's employees and the employees of Licensor's Affiliates are subject to the applicable policies of Licensor and such Affiliates, including, without limitation, policies regarding conflicts of interest, intellectual property and other matters. Licensee shall provide Licensor with any agreement it proposes to enter into, with respect to the subject matter of this Agreement, with any employee of Licensor or any Licensor's Affiliates (including, without limitation, any member of the medical or research staff of Licensor or any Affiliate of Licensor) for Licensor's prior review and shall not enter into any oral or written agreement with any such employee which conflicts with any such policy. Licensor shall provide Licensee, at Licensee's request, with copies of any such policies applicable to any such employee.
​
​
		6.	INDEMNIFICATION; INSURANCE; WARRANTY DISCLAIMER; NO CONFLICT

​
		6.1	Indemnification.

​
		(i)	Licensee shall indemnify, defend and hold harmless Licensor and Emory University, and their trustees, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns (the "Indemnitees"), against any liability, damage, loss or expense (including reasonable attorney's fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claim, suit, action, demand or judgment arising out of any theory of product liability (including, but not limited to, actions in the form of tort, warranty, or strict liability) concerning any product, process or service made, used or sold pursuant to any right or license granted under this Agreement.	

​

​

		(ii)	Licensees indemnification under (i) above shall not apply to any liability, damage, loss or expense to the extent that it is directly attributable to the negligent activities, reckless misconduct or intentional misconduct of the Indemnitees.	

​
​
		(iii)	Licensee agrees, at its own expense, to provide attorneys reasonably acceptable to the Licensor to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought.	

​

(iv)This Section 6.1 shall survive expiration or termination of this Agreement.
​
​
		6.2	Insurance.

​
		(i)	Prior to any clinical trial, commercial distribution of Licensed Product or the sale of product, process or service utilizing the Licensed Technology, by Licensee or by a sublicensee, Affiliate or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[***] per incident and $[***] annual aggregate through and up to the completion of Phase II clinical trials; $[***] per incident and $[***] annual aggregate after completion of Phase II and up to completion of Phase III clinical trials; and $[***] per incident and $[***] annual aggregate after first commercial sale of the Licensed Product. Such commercial general liability insurance shall provide (a) product liability coverage and (b) contractual liability coverage for Licensee's indemnification under Section 6.1 of this Agreement. If Licensee elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $[***] annual aggregate) such self-insurance program must be reasonably acceptable to the Emory, Licensor and the Risk Management Foundation of the Harvard Medical Institutions, Inc. The minimum amount of insurance coverage required under this Section 6.2 shall not be construed to create a limit of Licensee's liability with respect to its indemnification under Section 6.1 of this Agreement.	

​

(ii)Licensee shall provide Licensor with written evidence of such insurance upon request of Licensor. Licensee shall provide Licensor with written notice at least [***] days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain
​

​

replacement insurance providing comparable coverage within such [***] day period, Licensor shall have the right to terminate this Agreement effective at the end of such [***] day period without notice of any additional waiting periods.
​
​
		(iii)	Licensee shall maintain such commercial general liability insurance during (a) the period that any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a sublicensee, affiliate or agent of licensee and (b) a reasonable period after the period referred to in (iii)(a) above which in no event shall be less than [***] years.	

​
		(iv)	This Section 6.2 shall survive expiration or termination of this Agreement.	

​
		(v)	Any Sublicensee shall maintain insurance in favor of Licensor under the same terms as set forth above.	

​
​
		6.3	Warranty Disclaimer.

​
		(i)	LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY OF THE LICENSED TECHNOLOGY OR ANY LICENSED PRODUCTS AND HEREBY DISCLAIMS THE SAME.	

​
		(ii)	LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY THAT THE MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER RIGHT OF ANY PARTY AND HEREBY DISCLAIMS THE SAME.	

​

		7.	TERM AND TERMINATION

​

7.1Term. Unless terminated earlier under the provisions of this Agreement, this Agreement will expire when Licensee has no further obligation to make or cause to be made any royalty or other payment under Section 3 of this Agreement.
​
7.2Termination by Licensor. Licensor shall have the right to terminate this Agreement and the license granted thereunder upon the happening of any of the following events:
​

​

(i)Licensee fails to pay or cause to be paid any royalty or other payment which has become due to Licensor under Section 3 of this Agreement, within [***] days after receiving a written request from Licensor to make such payment or to cause such payment to be made;
​
		(ii)	Licensee fails to comply with any due diligence requirement provided for in Section 5.1 and has not cured such failure within [***] days after written notice from Licensor to Licensee specifying the nature of such failure; or	

​
		(iii)	Licensee is in breach of or default under any other provision of this Agreement and has not cured such breach or default within [***] days after written notice from Licensor to Licensee specifying the nature of such breach or default.	

​
(iv)Termination by Licensee. Licensee shall have the right to terminate this Agreement for any reason upon [***] days prior written notice to Licensor.
​
​

		7.3	Effect of Termination.

​

		(i)	Upon termination of this Agreement for any reason, nothing herein shall be construed to release either Party from any obligation that matured prior to the effective date of such termination.	

​
		(ii)	Upon any termination of this Agreement by Licensor, Licensee agrees to negotiate with Licensor in good faith reasonable business terms for Licensor to utilize and otherwise have the benefit of all regulatory approvals of, or clinical trials or other studies conducted on, and all filings made with regulatory agencies in connection with, the Licensed Technology in order to assist Licensor or its licensees in developing the Licensed Technology and obtaining any approvals required to make, have made, use, offer to sell or sell Licensed Products.	

​
(iii)The provisions of Sections 4.2 (Confidential Information), 4.3 (Enforcement of Intellectual Property Rights), 6.1 (Indemnification), 6.2 (Insurance), 6.3 (Warranty Disclaimer), and 8 (Dispute Resolution) shall survive termination of this Agreement for any reason.
​
​

(iv)Licensee and any Sublicensee may, after Termination, sell all Licensed Products which are in inventory at the time of termination, and complete and sell Licensed Products which Licensee can clearly demonstrate were in the process of manufacture at the time of such termination, provided
​

​

that Licensee shall pay to Licensor any royalties due on the sale of such Licensed Products and shall submit reports, in accordance with this Agreement.
​

		8.	DISPUTE RESOLUTION

​
8.1Any dispute or issue relating to or in connection with this Agreement (a "Dispute") shall initially be referred to Licensor's Director of Technology Ventures Office ("TYO"), Emory's Director of Office of Technology Transfer,("OTT") and Company's CEO to resolve the Dispute. However, notwithstanding any of the terms of this Section and without limiting any other remedies that may be available, each Party shall have the right to seek immediate injunctive relief and other equitable relief from any court of competent jurisdiction to enjoin any breach or violation of this Agreement concerning confidential information or any other intellectual property licensed under this Agreement, without any obligation to unde1iake extra-judicial dispute resolution of any such Dispute or claim or otherwise to comply with this Section
​

(b)If the Director of TVO, Director Emory's OTT, and Company's CEO are unable to resolve the Dispute within [***] days after such referral, then such Dispute shall be referred to a mediator who has been mutually selected by the Parties. If the Parties are unable to agree upon a mediator, then either Party may petition a court of competent jurisdiction in the Commonwealth of Massachusetts and such court shall appoint an independent mediator with relevant experience and sufficient qualifications to provide mediation services to the Parties.
​
(c)If the Parties are unable to resolve the Dispute with the assistance of a mediator within [***] business days of the selection or appointment thereof, the Dispute shall be referred to arbitration. The Dispute shall be finally settled by binding arbitration in accordance with this Agreement and the substantive laws of the Commonwealth of Massachusetts, following the Commercial Arbitration Rules of the American Arbitration Association ("AAA"). The venue for any arbitration hereunder shall be Boston, Massachusetts, United States, and each Party waives the defense of forum non conveniens and any other defense to personal jurisdiction on grounds of inconvenient forum or otherwise. The award of the arbitration shall be final and binding upon the Parties, and may be entered and enforced in any court of competent jurisdiction. Without limiting the foregoing, each Party consents to the jurisdiction of the state and federal courts in the Commonwealth of Massachusetts for purposes of any suit to compel mediation or arbitration and any suit to confirm and enforce an arbitration award.
​

(d)If a Party believes that it will be irreparably harmed during the arbitration process, such Party may seek injunctive relief in any
​

​

Massachusetts court having competent jurisdiction over the parties and the subject matter to enjoin any breach or violation pending an adjudication on the merits in arbitration. Further, without limiting such Party's right to seek injunctive relief from a court of competent jurisdiction, either Party may apply to the arbitral tribunal of the AAA seeking injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.
​
(e)Each Party shall bear its own costs in obtaining the dispute resolution, as outlined above. Nothing herein shall be interpreted to limit the rights of any part to seek injunctive relief or equitable relief pending alternative dispute resolution.
​
​
		9.	GENERAL

​
​
9.1Assignment. This Agreement shall be binding upon and shall inure to the benefit of each Party and each Party's respective transferees, successors and assigns, provided, however, that neither Party shall have the right to assign this Agreement or its rights and obligations hereunder to any other Person without the prior written consent of the other Party, except as expressly provided in this paragraph. Each Party may assign or otherwise transfer this Agreement and the License granted hereby and the rights acquired by it hereunder in connection with a sale or other transfer of such Party's entire business or that part of such Party's business to which the License granted hereby relates, provided, in all such cases, that any such assignee or transferee has agreed in writing to be bound by the terms and provisions of this Agreement or is so bound by operation of law. Any purported assignment in violation of the provisions of this paragraph shall be null and void.
​
9.2Entire Assignment/Amendments. This Agreement constitutes the entire and only agreement between the Parties relating to Licensed Invention, and all prior negotiations, representations, agreements and understandings are superseded hereby. No agreements amending, altering or supplementing the terms hereof may be made except by means of a written document signed by a duly authorized representative of each Party.
​
​

9.3Notices. Any notice, communication or payment required or permitted to be given or made hereunder shall be in writing and, except as otherwise expressly provided in this Agreement, shall be deemed given or made and effective (i) when delivered personally; or (ii) when delivered by telex or telecopy (if not a payment); or (iii) when received if sent by overnight express or mailed by certified, registered or regular mail, postage prepaid, addressed to parties at their address stated below, or to such other address as such party may designate by written notice in accordance with the provisions of this Section 9.3.
​

​

LICENSOR:
​
​
​
​
​
​
With a copy to:
​
​
​
​
LICENSEE:

Mark Chalek
Chief of Business Ventures
Beth Israel Deaconess Medical Center: BR-2 330 Brookline Avenue
Boston, MA 02215
Fax# 617-667-0537
​
Office of General Counsel CareGroup, Inc.
109 Brookline Ave., BR-3 Boston, MA 02215
​
Mark A. Tepper, Ph.D. Primatope Therapeutics Inc. 508 Dudley Rd, Suite 400
Newton, MA 02459
Fax: 617-795-2189
​

​
​

9.4Governing Law. This Agreement shall be construed and enforced in accordance with the domestic substantive laws of Massachusetts without regard to any choice or conflict of laws rule or principle that would result in the application of the domestic substantive law of any other jurisdiction other than (i) United States federal law, to the extent applicable and (ii) in regard to any question affecting the construction or effect of any patent, law of the jurisdiction under which such patent is granted.
​
9.5Headings. Headings included herein are for convenience only, and shall not be used to construe this Agreement.
​
9.6Independent Contractors. For the purpose of this Agreement and all services to be provided hereunder, each shall be, and shall be deemed to be, an independent contractor and not an agent, partner, joint venturer or employee of the other party. Neither party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other party, except as may be explicitly provided for herein or authorized in writing.
​

9.7Severability. If any provision of this Agreement shall be found by a court of competent jurisdiction to be void, invalid or unenforceable, the same shall either be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement.
​
9.8No Waiver. Failure of either party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved or to terminate this Agreement arising out of any subsequent default or breach.
​

​

9.9Limitation of Liability. Neither Party shall be liable to the other Party for indirect, incidental or consequential damages arising out of any of the terms or conditions of this Agreement or with respect to its performance or lack thereof.
​
9.10Counterparts. This Agreement may be executed in any number of counterparts, each of which shall constitute an original document, but all of which shall constitute the same agreement.
​
​
[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]
​

​

​
IN WI1NESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first set forth above.
​
​
THE BETH ISRAEL
DEACONESS MEDICAL CENTER
​
​
​
By: /s/ Mark Chalek​ ​
​
Title: Chief, Business Ventures
​
Mark Chalek
Chief, Business Ventures
Beth Israel Deaconess Medical Center
330 Brookline Avenue, FN-2
Boston, MA 02215

PRIMATOPE THERAPEUTICS INC
​
​
​
​
By: /s/ Mark Tepper​ ​
​
Title: President & CEO
​

​
​

1179259.02

​

​
​
​
​
​
​
Schedule 1.8
​
LICENSED FIELD
​
​
​
FIELD OF USE shall mean any and all uses and applications, including without limitation for the treatment, prevention or diagnosis of diseases or medical indications in humans or animals.
​

​

Schedule 1.10
​
LICENSED PATENTS
​
The following patents and patent applications:
​
[***]

​

Schedule 1.12
​
LICENSED TERRITORY
​
​
Worldwide
​
​
​
Schedule 1.13
BIOLOGICAL MATERIALS
[***]

​

Schedule 2.1 (ii)
​
PRE-EXISTING THIRD PARTY RIGHTS
​
​
US Government rights as described in Section 2.1 (i) of this Agreement.
​

​

Schedule 2.1 (iii)
​
​
LICENSOR'S RETAINED RIGHTS
​

​

Schedule 3.1(i)
​
LICENSING FEES
​
​
Upon execution of this Agreement, Licensee shall pay to Licensor [***] as a license signing fee.
​
Beginning on the second anniversary of the Effective Date, Licensee shall pay to Licensor a license maintenance fee of [***]. For the purpose of clarity the second anniversary will be November 1, 2015.
​
​
Each of the fees specified in this Schedule are non-refundable. The license maintenance fee will be creditable against any other payments due to Licensor under this Agreement in the same calendar year.
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​

​

Schedule 3.l(ii)
​
EQUITY INTEREST
​
​
​
​
​
		(a)	As used herein the following tem1s have the following definitions:

​

(i)"Common Stock" means shares of the Licensee's capital stock which have been designated as common stock.
​
(ii)"Fully Diluted Capital" means the total issued and outstanding Securities of the Licensee on a fully exercised, fully diluted, and on an as converted to Common Stock basis. With respect to any of the Licensee's Securities which are convertible into other Securities of the Licensee, if the conversion price of those Securities is not ascertainable at the time of the determination of the Fully Diluted Capital, the conversion price shall be deemed to be equal to the price at which the Licensee last issued Common Stock to an arm's length purchaser for value. With respect to any Securities allocated to a stock option plan or similar compensatory arrangement by the Licensee, all Securities allocated to any such plan or arrangement shall be deemed to be issued and outstanding whether or not any such Securities are then exercisable or subject to any grants.
​
(iii)"Pre-money Valuation" means the value of the Licensee immediately prior to the first closing of a Qualified Financing based on (1) the aggregate gross purchase price of the Securities in such Qualified Financing including consideration payable at the time of any closing and including consideration payable at any time thereafter or on a conditional or contingent basis, and (2) the percentage ownership being acquired by the purchasers (other than the Licensor) of Securities in that Qualified Financing.
​
(iv)"Qualified Financing" means any issuance by the Licensee of Securities to one or more arm's length purchaser(s) for value for which issuance the Pre-money Valuation of the Licensee plus the aggregate gross purchase price of the Securities being issued by the Licensee at the closing of the Qualified Financing is equal to or in excess of [***].
​

(v)"Securities" has the same meaning as the term "security" as defined in the Securities Act of 1933, as amended, including, without limitation, any equity security of any class or series, and any option, warrant, or other convertible security including debt securities which are conve1iible at any time or for any reason or under any conditions into equity securities.
​

(b)In partial consideration for the technology license granted to the Licensee pursuant to the License Agreement, the Licensee shall issue and deliver to the Licensor, within [***]
​

​

calendar days of the execution of the License Agreement and without any fee or consideration, shares of Common Stock which shall equal [***] of the Fully Diluted Capital. Thereafter, until the closing of a Qualified Financing, the following shall occur:
​
(i)if the Licensee issues any Securities other than in a Qualified Financing, the Licensee shall simultaneously issue and deliver to the Licensor, without any additional fee or consideration, from time to time, such number of additional shares of Common Stock so as to cause the Licensor to continue to own shares of Common Stock representing [***] of the Fully Diluted Capital of the Licensee; and
​
(ii)with respect to a Qualified Financing, the Licensee shall simultaneously issue and deliver to the Licensor, without any additional fee or consideration, such number of additional shares of Common Stock so as to cause the Licensor to own shares of Common Stock representing [***] of the Fully Diluted Capital of the Licensee assuming solely for the purposes of this Section (b)(ii) that only that number of Securities with aggregate consideration equal to (I) [***] minus (2) the Pre-money Valuation are sold to purchasers (other than the Licensor) in the Qualified Financing. By way of clarity if the Pre-money Valuation is equal to or greater than [***], no additional shares of Common Stock shall be issued to the Licensor under this Section (b)(ii).
​

​

Schedule 3.1(iii)
​
​
RUNNING ROYALTIES
​
In countries of the Territory where the using, importing, offering for sale or selling of Licensed Product would be covered by a Pending Claim, or, except for the license hereunder, be an infringement of a Valid Claim of the Licensed Patents, Licensee shall pay or cause to be paid to Licensor a running earned royalty equal to the Applicable Percentage of Net Sales of Licensed Products, as follows:
​
Beginning as of the Effective Date of this Agreement, Licensee shall pay Licensor a running earned royalty as follows:
​
[***]
​
All Net Sales amounts shall be annually aggregated, and cumulative for all indications. Licensee shall pay any applicable withholding taxes.
If Licensee or any Sublicensee is obligated or deems it reasonably necessary to pay a royalty to
any third party that is infringed by the manufacture, use or sale of a Licensed Product. Licensee and any Sublicensee shall be entitled to deduct the royalty payments made to such third party from the running royalty payments due under this Agreement; provided, however that in no event shall the royalties payable to Licensor be reduced to less than [***] percent of the amount due under this Agreement.
​
Licensee's obligation to pay a running royalty with respect to the Net Sale of any Licensed Product shall terminate on a country-by-country basis, upon expiration of any Licensed Patent applicable to the manufacture, use or sale of such Licensed Product.
​
Notwithstanding any other provision of this Agreement, in the case of any Net Sale of any Licensed Product which qualifies as a Licensed Product solely as a result of the application of Section l .13(ii) (i.e., a product whose manufacture, use or sale relies in whole or in part on some or all of the Licensed Knowhow but would not, absence the license granted by this Agreement, infringe any valid claim included in any Licensed Patent or any portion thereof), the Applicable Percentage shall be reduced by [***]% of the Applicable Percentage specified above.
​
Within [***] days of the end of each calendar quarter in which any Net Sales occur, Licensee shall calculate the running royalty amount owed to Licensor and shall remit to Licensor the amount owed to Licensor. Such payment shall be accompanied by a statement showing the calculation of the amount owed for each country, the total Net Sales of Licensed Product by country for that quarter, the exchange rate used to convert any royalty amounts into United States dollars and the total Net Sales for that quarter in all countries. For purposes of
​

​

determining when a sale of Licensed Product occurs, the sale shall be deemed to occur on the date of invoice to the purchaser of the Licensed Product.
​
​
​
Schedule 3.l(iv)
​
MINIMUM ROYALTIES
​
​
[***]

​

Schedule 3.l(v)
​
MILESTONE PAYMENTS
​
​
Licensee shall make the following payments to Licensor within [***] days of the initial occurrence of each of the following events:
​
​
Event

Amount

[***]
​
The foregoing milestone payments shall be non-refundable to Licensee and are not creditable against any other payments payable to Licensor under this Agreement.
​

​

Schedule 3.l(vi)
SUBLICENSING AND OTHER FEES
​
In the event Licensee shall receive, in connection with the grant to any third party or parties of a sublicense or other right, license, privilege or immunity to make, have made, use, offer to sell, sell or otherwise dispose of Licensed Products, any of the following forms of consideration, Licensee shall pay to Licensor within [***] days of Licensee's receipt of any such consideration the specified amount:
​
[***]
​
The foregoing payments shall be non-refundable to Licensee and are not creditable against any other payments payable to Licensor under this Agreement.
​

​

Schedule 4.1
​
PATENT PROSECUTION
​
​
Licensor shall be responsible for prosecuting and maintaining all Licensed Patents.
Without limiting the generality of the foregoing, Licensee shall reimburse Licensor for [***]. Licensee shall reimburse Licensor for all such expenses after the execution of the License within [***] days of receipt of invoice for the expenses. Licensee shall cooperate with Licensor in regard to such maintenance and prosecution. Licensor shall provide Licensee with copies of all filings and relevant documentation and an opportunity to comment thereon prior to their submission. Should Licensor determine to abandon prosecution of, or to cease to maintain, any Licensed Patent, in any jurisdiction, Licensor shall so notify Licensee and shall permit Licensee, should Licensee choose to do so, at Licensee's expense, to continue to prosecute or maintain such Licensed Patent in such jurisdiction, and Licensor shall cooperate with Licensee in regard thereto.
​

​

Schedule 5.1
​
SPECIFIC DUE DILIGENCE OBLIGATIONS
​
​
[***]

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]